Asher Chanan‐Khan
About
Asher Chanan‐Khan is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Asher Chanan‐Khan has authored 367 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 189 papers in Hematology, 167 papers in Genetics and 142 papers in Molecular Biology. Recurrent topics in Asher Chanan‐Khan's work include Multiple Myeloma Research and Treatments (166 papers), Chronic Lymphocytic Leukemia Research (163 papers) and Lymphoma Diagnosis and Treatment (83 papers). Asher Chanan‐Khan is often cited by papers focused on Multiple Myeloma Research and Treatments (166 papers), Chronic Lymphocytic Leukemia Research (163 papers) and Lymphoma Diagnosis and Treatment (83 papers). Asher Chanan‐Khan collaborates with scholars based in United States, Germany and Australia. Asher Chanan‐Khan's co-authors include Sagar Lonial, Sikander Ailawadhi, Kena C. Miller, Paul G. Richardson, Kenneth C. Anderson, Aneel Paulus, Taimur Sher, Edward A. Stadtmauer, S. Vincent Rajkumar and Myron S. Czuczman and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.
In The Last Decade
Asher Chanan‐Khan
352 papers receiving 10.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Asher Chanan‐Khan United States | 50 | 5.7k | 5.4k | 4.1k | 2.9k | 2.1k | 367 | 10.8k | ||
| Xavier Leleu France | 53 | 6.9k 1.2× | 6.4k 1.2× | 4.4k 1.1× | 3.0k 1.0× | 2.1k 1.0× | 457 | 11.4k | ||
| Christian Buske Germany | 53 | 3.9k 0.7× | 3.7k 0.7× | 2.2k 0.5× | 3.2k 1.1× | 2.5k 1.2× | 256 | 9.3k | ||
| Robert Schlossman United States | 54 | 7.1k 1.2× | 6.7k 1.2× | 4.7k 1.2× | 1.3k 0.5× | 1.3k 0.6× | 161 | 10.9k | ||
| Irene M. Ghobrial United States | 71 | 6.5k 1.1× | 8.6k 1.6× | 5.2k 1.3× | 4.6k 1.6× | 4.1k 1.9× | 484 | 17.1k | ||
| Mario Boccadoro Italy | 60 | 10.9k 1.9× | 8.3k 1.5× | 7.4k 1.8× | 2.2k 0.7× | 1.7k 0.8× | 479 | 15.9k | ||
| A. Keith Stewart United States | 57 | 7.7k 1.4× | 8.0k 1.5× | 4.6k 1.1× | 1.5k 0.5× | 1.1k 0.5× | 189 | 11.3k | ||
| Sonja Zweegman Netherlands | 55 | 6.5k 1.1× | 5.1k 0.9× | 4.6k 1.1× | 1.5k 0.5× | 574 0.3× | 334 | 10.4k | ||
| Ravi Vij United States | 46 | 6.5k 1.1× | 4.3k 0.8× | 4.1k 1.0× | 1.1k 0.4× | 730 0.3× | 469 | 9.6k | ||
| Joan Bladé Spain | 61 | 12.1k 2.1× | 9.3k 1.7× | 6.9k 1.7× | 2.4k 0.8× | 997 0.5× | 324 | 14.8k | ||
| Nelson Leung United States | 65 | 5.2k 0.9× | 9.6k 1.8× | 3.2k 0.8× | 3.1k 1.1× | 1.4k 0.7× | 435 | 15.4k |
Countries citing papers authored by Asher Chanan‐Khan
Since
Specialization
Citations
This map shows the geographic impact of Asher Chanan‐Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Chanan‐Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Chanan‐Khan more than expected).
Fields of papers citing papers by Asher Chanan‐Khan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Asher Chanan‐Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Chanan‐Khan. The network helps show where Asher Chanan‐Khan may publish in the future.
Co-authorship network of co-authors of Asher Chanan‐Khan
This figure shows the co-authorship network connecting the top 25 collaborators of Asher Chanan‐Khan. A scholar is included among the top collaborators of Asher Chanan‐Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asher Chanan‐Khan. Asher Chanan‐Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lasica, Masa, Sikander Ailawadhi, Chengcheng Fu, et al.. (2024). Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology. 42(16_suppl). 7078–7078.
2.
Ailawadhi, Sikander, Ryan D. Frank, David O. Hodge, et al.. (2024). Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer Journal. 14(1). 86–86.
3.
Paulus, Aneel, Fabio Malavasi, & Asher Chanan‐Khan. (2022). CD38 as a multifaceted immunotherapeutic target in CLL. Leukemia & lymphoma. 63(10). 2265–2275.
4.
Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494.
5.
Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399.
6.
Madamsetty, Vijay Sagar, Aneel Paulus, Sharoon Akhtar, et al.. (2020). Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. Leukemia & lymphoma. 61(10). 2399–2408.
7.
Reljic, Tea, Ernesto Ayala, Julio C. Chávez, et al.. (2020). Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome. Hematology/Oncology and Stem Cell Therapy. 14(1). 33–40.
8.
Kumar, Vivek, Sikander Ailawadhi, Aditya Mehta, et al.. (2019). Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal. 9(10). 75–75.
9.
Manna, Alak, Salman Ahmed, Sharoon Akhtar, et al.. (2019). Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 25(13). 3974–3985.
10.
Laali, Kenneth K., Frederick J. Troendle, Gabriela L. Borosky, et al.. (2018). Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity. ChemMedChem. 13(18). 1895–1908.
11.
Paulus, Aneel, Marie V. Coignet, Alak Manna, et al.. (2017). Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings. Blood. 130. 2178–2178.
12.
Lentzsch, Suzanne, Hang Quach, Asher Chanan‐Khan, et al.. (2017). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor. Blood. 130. 1852–1852.
13.
Olejniczak, Scott H., Ryan Cummings, Ana Mantilla, et al.. (2012). The Proteasome Activator PA200 Regulates Tumor Cell Responsiveness to Glutamine and Resistance to Ionizing Radiation. Molecular Cancer Research. 10(7). 937–944.
14.
Rodgers, George M., Pamela S. Becker, Morey A. Blinder, et al.. (2012). Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 10(5). 628–653.
15.
Swaika, Abhisek, Aneel Paulus, Kena C. Miller, et al.. (2012). Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients. PubMed. 10(4). 155–159.
16.
Richardson, Paul G., Asher Chanan‐Khan, Sagar Lonial, et al.. (2011). Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British Journal of Haematology. 153(6). 729–740.
17.
Richardson, Paul G., Asher Chanan‐Khan, Melissa Alsina, et al.. (2010). Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study. British Journal of Haematology. 150(4). 438–445.
18.
Chanan‐Khan, Asher, Kena C. Miller, David Lawrence, et al.. (2010). Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 117(10). 2127–2135.
19.
Chanan‐Khan, Asher, Kena C. Miller, Laurie Musial, et al.. (2006). Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. Journal of Clinical Oncology. 24(34). 5343–5349.
20.
O’Connor, Owen A., Emily Smith, Sridhar Srinivasan, et al.. (2004). Combined Targeting of the Proteasome and Bcl-2 Sensitizes Human B-Cell Lymphoma and Multiple Myeloma to Cyclophosphamide in In Vitro and In Vivo Models of These Diseases.. Blood. 104(11). 2484–2484.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Xavier Leleu Breakdown of academic impact, for papers by Christian Buske Breakdown of academic impact, for papers by Robert Schlossman Breakdown of academic impact, for papers by Irene M. Ghobrial Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Sonja Zweegman Breakdown of academic impact, for papers by Ravi Vij Breakdown of academic impact, for papers by Joan Bladé Breakdown of academic impact, for papers by Nelson Leung